Disclosed positions
| Evommune, Inc. | EVMN | COM SHS | $29,445,086 | 1,280,778 | SH | None |
| Inventiva S.A. | IVA | ADS | $13,064,700 | 2,354,000 | SH | None |
| Wave Life Sciences Ltd. | WVE | SHS | $5,437,500 | 750,000 | SH | None |
| Rani Therapeutics Holdings, Inc. | RANI | COM CL A | $2,694,941 | 3,667,585 | SH | None |
| Clene Nanomedicine Inc. | CLNN | COM NEW | $2,125,293 | 431,094 | SH | None |
| Surrozen, Inc. | Unresolved | *W EXP 08/01/203 | $2,400 | 150,000 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 1 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.